VCNX vs. EFTR, HEPA, CYCN, UPC, KTTA, CANF, BNOX, VIRI, CVKD, and PCSA
Should you be buying Vaccinex stock or one of its competitors? The main competitors of Vaccinex include eFFECTOR Therapeutics (EFTR), Hepion Pharmaceuticals (HEPA), Cyclerion Therapeutics (CYCN), Universe Pharmaceuticals (UPC), Pasithea Therapeutics (KTTA), Can-Fite BioPharma (CANF), Bionomics (BNOX), Virios Therapeutics (VIRI), Cadrenal Therapeutics (CVKD), and Processa Pharmaceuticals (PCSA). These companies are all part of the "pharmaceutical preparations" industry.
eFFECTOR Therapeutics (NASDAQ:EFTR) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and community ranking.
In the previous week, eFFECTOR Therapeutics had 4 more articles in the media than Vaccinex. MarketBeat recorded 6 mentions for eFFECTOR Therapeutics and 2 mentions for Vaccinex. eFFECTOR Therapeutics' average media sentiment score of 1.43 beat Vaccinex's score of 0.81 indicating that Vaccinex is being referred to more favorably in the news media.
eFFECTOR Therapeutics presently has a consensus price target of $24.00, indicating a potential upside of 1,100.00%. Given Vaccinex's higher probable upside, analysts clearly believe eFFECTOR Therapeutics is more favorable than Vaccinex.
eFFECTOR Therapeutics has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, Vaccinex has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.
Vaccinex's return on equity of 0.00% beat eFFECTOR Therapeutics' return on equity.
Vaccinex has lower revenue, but higher earnings than eFFECTOR Therapeutics. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.
57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 8.4% of eFFECTOR Therapeutics shares are owned by insiders. Comparatively, 51.5% of Vaccinex shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Vaccinex received 100 more outperform votes than eFFECTOR Therapeutics when rated by MarketBeat users. However, 79.31% of users gave eFFECTOR Therapeutics an outperform vote while only 60.00% of users gave Vaccinex an outperform vote.
Summary
eFFECTOR Therapeutics beats Vaccinex on 10 of the 16 factors compared between the two stocks.
Get Vaccinex News Delivered to You Automatically
Sign up to receive the latest news and ratings for VCNX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VCNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vaccinex Competitors List
Related Companies and Tools
